Table 1.
Baseline and disease characteristics
| Characteristic | Total (N = 63) |
|---|---|
| Median age (range), y | 66 (30-92) |
| Age ≥65 y | 36 (57) |
| Male sex | 26 (41) |
| ECOG performance status | |
| 0 | 33 (52) |
| 1 | 25 (40) |
| 2 | 5 (8) |
| MZL subtype | |
| Extranodal | 32 (51) |
| Splenic | 14 (22) |
| Nodal | 17 (27) |
| Bulky disease ≥6 cm | 14 (22) |
| B symptoms | 15 (24) |
| Bone marrow involvement | 21 (33) |
| Baseline cytopenias | |
| Any cytopenia | 27 (43) |
| Hemoglobin ≤11 g/dL | 27 (43) |
| Platelet count ≤100 × 109/L | 6 (10) |
| Absolute neutrophil count ≤1.5 × 109/L | 1 (2) |
| Lactate dehydrogenase | |
| Median lactate dehydrogenase (range), U/L | 227 (117-1198) |
| ≥350 U/L | 12 (19) |
| Creatinine clearance <60 mL/min | 9 (14) |
| Median time from initial diagnosis (range), months | 45 (8-271) |
| Median time from first treatment (range), months | 38 (1-271) |
| Median time from last prior therapy (range), months | 12 (0.8-113) |
| No. of prior systemic therapies | |
| Median no. of prior therapies (range) | 2 (1-9) |
| 1 prior therapy | 23 (37) |
| 2 prior therapies | 18 (29) |
| ≥3 prior therapies | 22 (35) |
| Types of prior therapies | |
| Rituximab monotherapy only | 17 (27) |
| Rituximab-based chemoimmunotherapy | 40 (63) |
| Radiation | 9 (14) |
| Splenectomy | 4 (6) |
| Autologous hematopoietic stem cell transplantation | 2 (3) |
| Median no. of prior rituximab treatments (range) | 1 (1-7) |
| Refractory to last prior systemic therapy | 14 (22) |
Data are presented as n (%) of patients unless indicated otherwise.